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Proving how exposures affect health outcomes can be
blematic in observational studies. Even if an exposure
 an outcome are associated, the direction of causality
 be difﬁcult to ascertain because health outcomes can
 to changes in behaviour which can affect exposures
nafo` and Araya, 2010). Mendelian randomization
dies may help to shed light on these relationships by
using genetic variants, such as single nucleotide
polymorphisms (SNPs) (see Table 1 for deﬁnition), as
instrumental variables for measured lifestyle exposures
(Davey Smith and Ebrahim, 2003). Mendelian randomiza-
tion studies can be used for two related purposes: (1) to
provide evidence for the existence of causal associations,
and (2) to enable accurate estimation of the magnitude of
the effect of lifelong exposure to a risk factor on an
outcome (Davey Smith and Ebrahim, 2004).
As is the case for instrumental variable methods
generally, for Mendelian randomization studies to be
useful genetic variants must be robustly associated with
the exposure of interest (Davey Smith and Ebrahim, 2005;
Lawlor et al., 2008b). Despite this, recent Mendelian
randomization studies conducted by Wehby et al.
(2011a,b, 2012) have used genetic variants as instruments
for smoking heaviness which were not shown to be
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A B S T R A C T
Mendelian randomization methods, which use genetic variants as instrumental variables
for exposures of interest to overcome problems of confounding and reverse causality, are
becoming widespread for assessing causal relationships in epidemiological studies. The
main purpose of this paper is to demonstrate how results can be biased if researchers
select genetic variants on the basis of their association with the exposure in their own
dataset, as often happens in candidate gene analyses. This can lead to estimates that
indicate apparent ‘‘causal’’ relationships, despite there being no true effect of the exposure.
In addition, we discuss the potential bias in estimates of magnitudes of effect from
Mendelian randomization analyses when the measured exposure is a poor proxy for the
true underlying exposure. We illustrate these points with speciﬁc reference to tobacco
research.
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association studies. Whilst the authors acknowledge that
these variants have not been consistently associated with
smoking phenotypes, they suggest that the variants
provide evidence of causal effects of smoking on body
weight (Wehby et al., 2012) and smoking in pregnancy on
birthweight (Wehby et al., 2011b) and risk of orofacial
clefts in offspring (Wehby et al., 2011a). In addition, the
authors use the genetic variants to estimate the magnitude
of effect of smoking heaviness on their outcomes of
interest (Wehby et al., 2011a,b, 2012). Even if the variants
they use are truly associated with smoking behaviour, this
is likely to produce incorrect estimates of the effect size of
smoking on the outcome.
1.1. Aims
In this paper, we aim: (1) to illustrate, using a data
simulation, why inferences based on the results of
Mendelian randomization studies using genetic variants
selected based on their association in a single sample are
likely to be misleading and (2) to demonstrate why
estimating the magnitudes of causal effects in cases where
the measured exposure is not the same as the underlying
exposure captured by the variant is problematic. We
discuss these issues with reference to the speciﬁc case of
tobacco as an exposure, but these principles can be applied
more widely to Mendelian randomization and instru-
mental variable analyses.
1.2. Assumptions of Mendelian randomization
The principle of Mendelian randomization relies on the
basic (but approximate) laws of Mendelian genetics
(segregation and independent assortment). If these two
laws hold, then at a population level, genetic variants will
not be associated with the confounding factors that
generally distort conventional observational studies
(Davey Smith and Ebrahim, 2003; Davey Smith, 2011).
In addition, genetic variants will not be affected by reverse
causality (Davey Smith and Ebrahim, 2003). Epidemiolo-
gical studies increasingly use Mendelian randomization to
provide robust evidence of underlying causal mechanisms
in a number of areas of health research including
cardiovascular disease, cancer and mental health (Casas
et al., 2005; Davey Smith et al., 2005; Benn et al., 2011;
Scott et al., 2011; Interleukin-6 Receptor Mendelian
Randomisation Analysis et al., 2012; Nordestgaard et al.,
2012; Voight et al., 2012; Carslake et al., 2013).
For a SNP to be a valid instrumental variable, the
following assumptions must hold: (1) the SNP should be
reliably associated with the exposure, (2) the SNP should
only be associated with the outcome through the exposure
of interest (the ‘‘exclusion restriction’’) and (3) the SNP
should be independent of other factors affecting the
outcome (confounders) (Angrist et al., 1996; Lawlor et al.,
2008b; Wehby et al., 2008; Clarke and Windmeijer, 2012).
Moreover, to use Mendelian randomization for accurate
estimation of effect sizes in mediation analysis using a
measured exposure, the measured exposure should
accurately capture the true causal exposure (Lawlor
et al., 2008a; Pierce and VanderWeele, 2012).
2. Use of genetic variants selected in a single sample
2.1. Genetic variants for tobacco research
Large consortium-based genome wide association
studies have found genetic variants robustly associated
with smoking behaviours (Thorgeirsson et al., 2008;
Furberg et al., 2010; Liu et al., 2010). One genetic variant
that has been highlighted by these studies, amongst others,
is located in the nicotinic receptor gene cluster CHRNA5–
A3–B4 on chromosome 15. Two SNPs within this region,
rs16969968 and rs1051730, which are in linkage dis-
equilibrium and can be used interchangeably in studies on
Europeans, consistently associate with measures of
heaviness of smoking (e.g., cigarettes per day or biomar-
kers of nicotine exposure) (Freathy et al., 2009; Munafo`
et al., 2012). Smokers with a single copy of the smoking
increasing allele smoke on average one extra cigarette per
day compared to those with no copies. The effects of the
SNP are additive, so people with two copies of the smoking
increasing allele on average smoke two additional cigar-
ettes a day (Ware et al., 2011). The strength and
consistency of this association make these variants
suitable instruments for use in Mendelian randomization
studies. The second assumption of instrumental variable
analysis, that the SNP should only be associated with the
outcome through the exposure of interest, is rarely fully
testable (Glymour et al., 2012). In Mendelian randomiza-
tion, this assumption may be violated if the genetic variant
has pleiotropic effects, is in linkage disequilibrium with
another variant of differing function or if its effects are
Table 1
Deﬁnitions of genetic terms for Mendelian randomization.
Term Deﬁnition
Allele One form of a genetic variant
Canalization Process of developmental compensation for the effects of a genetic variant which may disrupt
normal development
Genetic variant Part of the genetic code for which there is more than one form in the population. This can be a single
nucleotide polymorphism but other forms of variation exist
Genome wide association study (GWAS) Hypothesis-free study which investigates associations of a large number of genetic variants across
the whole genome with a trait of interest
Linkage disequilibrium Non-random association between genetic variants at different positions along the chromosome
Pleiotropic Inﬂuencing more than one phenotypic trait
Single nucleotide polymorphism (SNP) Variation at a single nucleotide base pair in the DNA sequence
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ever, the biological function of the nicotinic receptor
e cluster and evidence from epidemiological studies
gest that this variant is likely to affect outcomes only
ough tobacco exposure (for a further discussion of this
 Section 3). In addition, if the variant is associated
h an outcome in smokers or former smokers but not
er smokers, this is a good indication that the
ociation is fully mediated through tobacco exposure
athy et al., 2011). The rs1051730 SNP has been used
Mendelian randomization studies to investigate the
sal effect of cigarette smoking on body mass index,
ression anxiety and birthweight of offspring (Freathy
l., 2011; Lewis et al., 2011; Bjorngaard et al., 2013;
rell et al., 2012).
Despite the identiﬁcation of variants in the CHRNA5–
B4 gene cluster as suitable instruments, Wehby et al.
11a,b, 2012) use other variants (in DRD2, MAOA, DRD4,
T, GABBR2, CYP2D6) as instruments for smoking
viness in their Mendelian randomization studies. The
hors justify this approach by emphasizing the plausible
logical roles of their chosen variants in smoking
aviour. However, this justiﬁcation is questionable
en that the candidate gene approach for ﬁnding
ctional genetic variants has had limited success,
lding few replicable associations and many false
itives (Colhoun et al., 2003; Sleiman and Grant,
0; Lawlor et al., 2008b). If these common variants
 truly associated with the exposure, these associations
uld have been detected in the large genome wide
ociation studies of smoking behaviour. We calculated
t the largest of these studies, conducted by the TAG
sortium, which included 74,000 smokers had 80%
er to detect variants explaining as little as 0.05% of the
iance in cigarettes per day (Furberg et al., 2010). Genetic
iation in the CHRNA5–A3–B4 gene cluster explains
ut 1% of the variance in cigarettes per day (Munafo`
l., 2012).
 Data simulation
Below, we show why selecting variants based on their
ociation in a single sample can introduce bias into
ndelian randomization studies. We generated contin-
s exposure (X) and outcome (Y) variables for 10,000
ividuals using the following formulae:
 a1Z þ e
 b1X þ u;
ere Z is a binary instrument with a frequency of 0.3 and
d u (the error terms) are jointly normally distributed
tinuous variables with a correlation coefﬁcient of (r) of
:

 N 0
0
 
;
1 r
r 1
  
illustrate an example where the association of the SNP
 the exposure is well established, and where the
Mendelian randomization are unbiased, we set a1 = 0.5 and
b1 = 0.3, the raw association between X and Y from linear
regression was positive (beta a = 0.26, 95% CI: 0.25, 0.28)
(see Table 2). However, as we know from the negative
value of b1, the true effect of X on Y is negative. Hence the
linear regression estimate was biased and confounded by
the error terms. In contrast, the estimate of the effect of X
on Y from a two-stage least-squares regression, using the
instrument Z, was negative and equal to the ‘‘true’’ value of
b1 (beta coefﬁcient 0.29, 95% CI: 0.37, 0.21). This
demonstrates that in the presence of confounding, when
there is a robust relationship between the instrument and
the exposure, Mendelian randomization, and more broadly
instrumental variable analysis, can give an unbiased
estimate.
We next expand our simulation to demonstrate how
biases can occur if instruments are selected based on their
observed associations with the exposure in the sample
within which the Mendelian randomization experiment is
being carried out. To simulate an example in which there is
no effect of the exposure on the outcome, we set b1 = 0, so
the outcome and exposure were only correlated (correla-
tion = 0.6) due to the error terms. Thus the association of
the exposure and outcome is confounded. This means that
if our estimation model (estimator) is correct, then it
should ﬁnd no effect of the exposure on the outcome. If our
estimator is incorrect and we ﬁnd a relationship between
the outcome and the exposure, then it suggests our
estimator is biased.
Next, to simulate the selection of genetic instruments
within a sample, we randomly generated 1000 binary
variables (Z) to simulate the SNPs (all had a frequency of
0.3). Since these instruments were randomly generated,
there was no underlying effect of the SNPs on the exposure
(a1 = 0). We used a binary instrument in a one instrument
and one exposure example for simplicity, but these results
are generalizable to additive genetic models or Mendelian
randomization studies using multiple genetic variants
(Pierce et al., 2011; Clarke and Windmeijer, 2012). We
estimated the association of each SNP with the exposure, X,
using robust linear regression. As expected, by chance,
roughly 5% of these SNPs were associated with the
exposure (using a p-value cut-off of 0.05).
We selected the ten instruments most strongly
associated with the exposure and ran a two stage least
squares regression on the outcome using each of these
instruments in turn. Table 3 presents the effect sizes and p-
values for the association of the instrument with the
exposure and the outcome along with the F-statistic (a
measure of the strength of the association of instrument
and exposure).
Of the ten instruments selected, three had an F-statistic
Table 2
Results of data simulation showing unbiased estimate from two-stage
least-squares regression in the presence of confounding.
Model Beta (95% CI)a
Y on X (linear regression) 0.26 (0.25, 0.28)
Y on X (two stage least squares) 0.29 (0.37, 0.21)
a True value of beta from simulation is 0.3.ve the commonly used cut off point of 10, suggestingervational association is biased, but estimates from abo
A.E. Taylor et al. / Economics and Human Biology 13 (2014) 99–106102that the associations of instruments and exposure were
strong enough for the instrumental variable estimates to
be unbiased (Stock et al., 2002). Using two-stage least-
squares regression, ﬁve of the instruments showed strong
or moderate evidence for associations with the outcome (p
values <0.01), and two further instruments were weakly
associated (p values <0.1). However, we know that no
‘‘true’’ relationship exists, because of how we generated
the data. Therefore, these instruments, and speciﬁcally
how we selected the instruments biased the two-stage
least squares estimates of the effect of the exposure on the
outcome.
Use of inappropriate genetic variants is not a problem
speciﬁc to studies of tobacco research (Fletcher and Lehrer,
2011), but this example illustrates this problem well
because of the availability of good instruments for smoking
behaviour. The importance of this issue more generally in
Mendelian randomization studies has been highlighted
previously by Lawlor et al. (2008b) with reference to
smoking- and obesity-related variants.
2.3. The Beavis effect
Even when a variant discovered in a single sample is
truly associated with an exposure, the effect sizes of
variants identiﬁed within a single sample are, by the
nature of their discovery, likely to be larger than in the
overall population (the Beavis effect, or Winner’s Curse)
(Goring et al., 2001; Ioannidis, 2008; Burgess et al., 2011).
For example, suppose a variant is associated with a one
unit increase in an exposure variable and a two fold
increase in the risk of a disease outcome. The estimate from
a two stage least squares regression will imply that a one
unit increase in the exposure doubles the risk of disease.
However, in a sample where the effect of the variant on the
exposure is inﬂated and is associated with a two unit
increase in the exposure, the two stage least squares
regression will imply that a one unit increase in the
exposure would increase disease risk by
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2 ¼ 1:4
p
fold.
Thus, using genetic variants which have not demonstrated
consistently strong associations with the exposure of
interest is likely to bias instrumental variable estimates,
with the Beavis effect leading to an underestimation of the
strength of exposure–outcome associations.
Mathematically, this is explained by the following
formula. The instrumental variable estimator is the
association of the outcome and the instrument divided
by the association of the exposure and the instrument:
bIV ¼
covðy; zÞ
covðx; zÞ
Thus, if the denominator, cov(x, z) is larger, and the
numerator cov(y, z) remains constant, the estimated effect,
bIV, will be smaller.
3. Biases in magnitudes of effects from instrumental
variable analysis
Mendelian randomization can provide very good
estimates of the magnitude of effects of long term
exposure to a risk factor on outcomes (Davey Smith and
Ebrahim, 2005; Ference et al., 2012). However, when the
phenotypic exposure of interest (e.g., cigarettes per day)
does not adequately capture the ‘‘causal’’ exposure
through which the genetic variant operates (e.g., lifetime
exposure to tobacco), estimates from two-stage least-
squares regression may be biased. In such cases, the second
assumption of instrumental variable analysis (the exclu-
sion restriction assumption) is violated. The genetic
variant is still a valid instrument for the underlying
phenotype of interest and can therefore still provide
evidence of causality. However, it is not a valid instrument
for the effect of the measured phenotype on the outcome
and so magnitudes of effect are likely to be incorrect
(Glymour et al., 2012). This principle also applies more
widely to instrumental variable analyses using non genetic
instruments, but this issue has not been well-developed in
the econometrics or statistics literatures.
In tobacco research, self-reported measures of smoking
behaviour (such as number of cigarettes smoked per day)
may be inadequate phenotypes because people smoke
cigarettes differently. For example, there is variation in the
number of puffs taken, volume of smoke inhaled or how far
down the cigarette is smoked before it is discarded
(Strasser et al., 2007; McNeill and Munafo`, 2013). Objective
measures of tobacco exposure (e.g., level of cotinine, the
Table 3
Regression statistics of 10 most strongly associated randomly generated instruments.
Association of instrument with exposurea Association of exposure with outcomeb F statisticc
Beta SE p-Value Beta SE p-Value
Instrument 1 0.078 0.021 <0.001 0.436 0.222 0.05 13.66
Instrument 2 0.072 0.021 0.001 0.902 0.255 <0.001 11.48
Instrument 3 0.070 0.021 0.001 0.304 0.260 0.24 10.89
Instrument 4 0.064 0.021 0.002 0.123 0.305 0.69 9.31
Instrument 5 0.065 0.021 0.002 0.488 0.265 0.07 9.58
Instrument 6 0.063 0.021 0.003 0.757 0.280 0.007 8.79
Instrument 7 0.062 0.021 0.003 1.024 0.314 0.001 8.55
Instrument 8 0.059 0.021 0.005 0.04 0.352 0.91 7.92
Instrument 9 0.060 0.021 0.005 0.97 0.319 0.002 7.96
Instrument 10 0.058 0.021 0.006 0.934 0.320 0.003 7.53
a From linear regression of exposure on instrument.
b From 2-stage least squares regression of outcome on exposure using the instrument.
c F-statistic for strength of instrument.
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A.E. Taylor et al. / Economics and Human Biology 13 (2014) 99–106 103ary metabolite of nicotine) are likely to provide more
id assessment of actual biological exposure (i.e., the
ount of smoked inhaled). For example, the rs1051370/
6969968 variants are considerably more strongly
ociated with circulating levels of cotinine, than with
-reported daily cigarette consumption, explaining 4%
 1% of the variance in these phenotypes respectively
skitalo et al., 2009; Munafo` et al., 2012). Researchers
ly have data on phenotypes such as cotinine, and often
 a proxy measure such as self-reported cigarette
oking rates.
This issue is illustrated in Fig. 1. We are particularly
rested in the effect (a) of lifetime exposure to tobacco
oke (X) on an outcome measure (Y) (see Fig. 1A).
ortunately, we may only have data on cigarettes
oked per day (X2), which is associated with but does
 fully capture lifetime exposure (see Fig. 1B). The raw
ociation of smoking on the outcome is confounded by
 unobserved variable U (the error terms in our
ulations). The genetic variant (Z), not only affects the
l lifetime exposure (b), but also the number of
rettes smoked (c). According to the second assumption
nstrumental variable analysis, Z should only affect the
come through its effect on the number of cigarettes
oked per day (X2) but in this case it also affects the
come through lifetime exposure to tobacco smoke (X).
In the example above, if we adjust the association of the
iant (Z) with the outcome (Y) for the measured
notype (X2) we would not expect the association to
ppear because Z still affects Y through lifetime
osure to tobacco smoke (X). This issue has generated
ate in the literature; the residual association observed
between the CHRNA5–A3–B4 variants and lung cancer
following adjustment for cigarettes per day has led to
suggestions of a direct effect of the variant on lung cancer
which does not operate though smoking (Lips et al., 2010;
Wang et al., 2010a). However, Munafo` et al. (2012)
calculated that association between the variant and lung
cancer was consistent with full mediation through tobacco
exposure if cotinine were used as an intermediate measure
of tobacco exposure rather than cigarettes per day.
Therefore, the apparent direct association between these
variants and lung cancer is likely to be a function of poor
tobacco exposure measurement. This has important
implications for the use of two-stage least-squares
regression in Mendelian randomization analyses of smok-
ing. If the measured exposure does not capture all
dimensions of the relevant exposure domain, we can still
infer a causal relationship, but cannot obtain an accurate
estimate of the effect size of the underlying causal
exposure. Thus the effect sizes presented in papers using
cigarettes per day as the measured exposure of interest are
likely to be subject to bias and should be interpreted with
caution. It should be noted that this differs from the issue
of random and systematic measurement error in the
exposure phenotype, as discussed by Pierce and Vander-
Weele (2012). This is because even if cigarettes per day
were measured perfectly, this phenotype would not
adequately capture tobacco exposure.
Whilst this is a particular issue for studies of tobacco
use, this is also relevant for Mendelian randomization
studies of other exposures. For example, estimates from
Mendelian randomization studies using variants which
affect caffeine consumption may be biased if the measured
phenotype is number of cups of coffee consumed per day
because this measure does not account for caffeine content
of each cup. Glymour et al. (2012) also discuss this issue in
relation to incorrect speciﬁcation of the appropriate causal
time period for an exposure, using body mass index as an
example.
4. Conclusions
The results of Mendelian randomization studies, based
on genetic variants chosen because of their association
with the exposure in any one sample, do not contribute
useful evidence of the effects of exposures on health
outcomes. It is essential for Mendelian randomization
studies to use genetic variants that are robustly associated
with the exposure of interest. Fortunately, this is now
possible for a number of exposures, including tobacco,
generally because of variants identiﬁed in large genome
wide association studies and replicated in independent
samples (Timpson et al., 2005; Frayling et al., 2007; Hazra
et al., 2008; Furberg et al., 2010; Wang et al., 2010b; Voight
et al., 2012). Mendelian randomization studies, as well as
establishing causal associations, can provide good esti-
mates of the magnitudes of effect between exposures and
outcomes as they are free from bias by confounding.
However, estimates may be biased if the measured
exposures are not the same underlying exposure as that
represented by the genetic variant. Crucially, even if the
underlying causal exposure is perfectly measured, if the
b a
YXZ
U
c
a
X2
YXZ
U
b
A)
B)
1. Directed acyclic graphs for Mendelian randomization analyses of
otal lifetime exposure to tobacco smoke and (B) reported number of
rettes smoked per day with outcome measures. Observed variables
denoted using squares, unobserved variables are denoted using
es, causal effects have arrows. Dashed lines represent non-causal
ciations. X: total lifetime exposure to tobacco smoke, X2: reported
ber of cigarettes smoked per day, a genetic variant (Z), outcome (Y),
 an unobserved confounder (U).
A.E. Taylor et al. / Economics and Human Biology 13 (2014) 99–106104variant additionally affects the outcome through a
different pathway, neither causality nor strength of
associations can be estimated. Mendelian randomization
has the potential to be a valuable tool to further our
understanding of the aetiology of disease. Researchers will
only realize this potential if they base their studies on well-
characterized variants and are cautious about making
inferences about magnitudes of the relationships between
observed phenotypes and outcomes.
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